Alopecia

Veradermics initiates a groundbreaking trial for VDPHL01, an oral minoxidil treatment, addressing female pattern hair loss with innovative solutions.

Experts discuss hair loss challenges and treatments for skin of color, highlighting the importance of early intervention and accurate diagnosis.

At 52 weeks, the data presented at Fall Clinical showed that 64.8% and 63.3% of adolescents on baricitinib 4 mg achieved significant eyebrow and eyelash regrowth, respectively.

The trial evaluates ritlecitinib's efficacy for severe alopecia areata, utilizing innovative external placebo controls for enhanced patient outcomes.

The investigational extended-release tablet maintained therapeutic plasma levels while avoiding peaks linked to cardiovascular risk.

Upadacitinib shows promising results in treating severe alopecia areata, achieving significant hair regrowth and setting new efficacy standards in therapy.

Jerry Shapiro, MD, shares innovative strategies for diagnosing and managing scarring alopecia at Maui Derm NP+PA Fall 2025, enhancing patient outcomes.

Alopecia areata treatment advances with targeted therapies, improving patient outcomes and access while addressing the emotional impact of hair loss.

Happy Head's StrandIQ system revolutionizes hair loss treatment with personalized genetic analysis, enhancing hair growth and scalp health for individuals.

Explore the latest breakthroughs in treatment and research during Hair Loss Awareness Month, enhancing understanding and patient care for hair loss disorders.

Research highlights that educational videos on standardized clinical photography protocols significantly lead to better management and treatment outcomes for patients with alopecia.

Key regulatory milestones for MAL-838, a novel sCD83-based, hormone-free hair growth ingredient, are paving the way for the market launch of a microbiome-friendly 8T3 product line.

In this exclusive Q&A, Alan J. Bauman, MD, shares expert insights on innovative hair loss treatments, early intervention strategies, and the future of alopecia care.

AbbVie's upadacitinib showed promising results in treating severe alopecia areata, achieving significant hair regrowth in pivotal phase 3 trials.

Nektar Therapeutics advances alopecia areata treatment with FDA's Fast Track designation for rezpegaldesleukin, targeting immune modulation in chronic hair loss.

Tina Bhutani, MD, shares vital insights on psoriasis management, sleep's role in dermatology, and new alopecia areata treatments at Elevate-Derm Summer 2025.

A first-of-its-kind study reveals artificial intelligence (AI)-driven insights on hair loss trends, highlighting the impact of genetics, hormones, and COVID-19 on alopecia.

Sun Pharmaceuticals has launched deuruxolitinib (Leqselvi) in the US, offering a new treatment for adults with severe alopecia areata.

A systematic review reveals critical diagnostic gaps in hair loss treatment for patients with skin of color, urging improved training and protocols in dermatology.

A recent study reveals a significant link between alopecia areata severity and increased risk of atopic dermatitis, especially in adolescents.

From JAK inhibitors to trichoscopy and contact allergy clues, experts at SDPA 2025 shared their top clinical pearls for managing alopecia and hair loss.

Maria Hordinsky, MD, urges dermatology clinicians to consider allergic contact dermatitis when scarring alopecia treatments fail.

David Cotter, MD, PhD, discusses diagnosing alopecia areata and selecting systemic treatments, including JAK inhibitors, from his SDPA 2025 presentation.

Amy Spizuoco, DO, FAOCD, shared how trichoscopy enhances alopecia evaluation by improving diagnostic speed, accuracy, and reducing biopsy need.

PP405 shows promise for hair regrowth in phase 2a trial, with 31% seeing >20% density increase; phase 3 studies are planned for 2026.